Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|October 30, 2017

Plate Reader for Automated Characterization of Macromolecules and Nanoparticles

Wyatt Technology has added the DynaPro Plate Reader III to its macromolecular and nanoparticle characterization product offerings.

The DynaPro Plate Reader III from Wyatt Technology is an integrated instrument for automated characterization of size, molecular weight, aggregation, and stability of macromolecules and nanoparticles.

The instrument, which combines both dynamic light scattering and static light scattering approaches, contains a single, fully automated platform with measurements taken directly in 96, 384, or 1536 microwell plates. It can rapidly screen proteins, nanoparticles, colloids, and macromolecules to determine their size, molecular weight, aggregation, and stability profiles using a minimum of 4 μL of sample.

Additionally, the instrument can characterize both conformational and colloidal stability indicators like Tonset, Tagg, A2 and kD by running a temperature ramp or concentration series. Scientists can also perform viscosity determinations for the viability of biopharmaceuticals, and use the built-in camera to image each for additional insight.

Source: Wyatt Technology


Related to this article

The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.